Shyndec subsidiary gets approval for bumetanide injection

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Sinopharm Gensheng Pharmaceutical Co., Ltd., has obtained a drug registration certificate from the National Medical Products Administration for Bumetanide Injection. The drug, classified as a chemical medicine Class 3, has the registration certificate number 2025S03748. Sinopharm Gensheng Pharmaceutical Co., Ltd. is listed as both the marketing authorization holder and the manufacturer.

Bumetanide Injection is indicated for various conditions, including edematous diseases (such as congestive heart failure, liver cirrhosis, kidney diseases), hypertension, prevention of acute renal failure, hyperkalemia, hypercalcemia, dilutional hyponatremia, and acute drug or toxin poisoning. According to the Minai Network database, national public medical institution sales of Bumetanide Injection in 2024 amounted to RMB 468,870,000.

The total research and development investment by Sinopharm Gensheng for this project is approximately RMB 4,620,000. This approval is expected to strengthen the company's competitive position in the cardiovascular drug market.